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1.  Abstract 
Mass spectrometry (MS) has longstanding applications in radiochemistry laboratories, stemming 
from carbon-dating. However, research on the development of radiotracers for molecular imaging 
with either positron emission tomography (PET) or single photon emission computed tomography 
(SPECT) has yet to take full advantage of MS.  This inertia has been attributed to the relatively low 
concentrations of radiopharmaceutical formulations and lack of access to the required MS equipment 
due to the high costs for purchase and maintenance of specialized MS systems. To date, single 
quadrupole (SQ)-MS coupled to liquid chromatography (LC) systems is the main form of MS that 
has been used in radiochemistry laboratories. These LC/MS systems are primarily used for assessing 
the chemical purity of radiolabeling precursor or standard molecules but also have applications in the 
determination of metabolites. In this review, we highlight personal experiences using a compact SQ-
MS in our PET radiochemistry laboratories.  Herein, we will describe a pre-concentration system to 
detect dilute radiopharmaceutical formulations and metabolite analyses by SQ-MS. Selected 
examples where SQ-MS was critical for optimization of radiochemical reactions and for unequivocal 
characterization of radiotracers are showcased. We also illustrate examples where SQ-MS can be 
applied in identification of radiometal complexes and development of a new purification 
methodology for Pd-metal-catalyzed radiofluorination reactions, shedding light on the identity of 
metal complexes present in the labelling solution.  
 
2.  Introduction 
Mass spectrometry (MS) is among the most well-established structural characterization methods used 
in the field of chemistry.1-6 MS has an established role in radiochemistry, particularly in radiocarbon 
dating.7  For instance, the introduction of accelerator mass spectrometry (AMS) technology as a 
means of measuring natural levels of 14C has been described as the "Third Radiocarbon Revolution."8 
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Elsewhere in radiochemistry, single quadrupole (SQ)-MS has become the most widely used MS 
method. In combination with liquid chromatography (LC) systems, LC/MS has become 
commonplace for standard quality control analysis of radioactive precursors and standards. LC/MS 
is also used increasingly for detection of metabolites/radiometabolites to assess radiochemical 
stability in vitro and ex vivo, as well as to identify potential radiotracers for neuroimaging.9-12  
Whereas radiochemistry with 3H and 14C have benefitted from the advances of MS, radiochemistry 
for molecular imaging by positron emission tomography (PET) or single photon emission computed 
tomography (SPECT) has yet to take full advantage of MS technology.  The historically high cost of 
MS purchase, maintenance and operation of this specialized instrumentation are likely key factors 
which have held back MS from more widespread use in PET or SPECT radiochemistry laboratories.  
Furthermore, the relatively low concentrations (vide infra) of radiopharmaceutical formulations, and 
the regulatory restrictions around radioactivity in a central core MS laboratory, have also impeded 
access of this technology to PET and SPECT chemists.  
 Our radiopharmaceutical programs focus on the development of novel radiochemical 
reactions and on the characterization of new PET radiotracers for medical imaging in drug discovery 
and clinical research.13 The majority of our clinical research employs two radionuclides: carbon-11 
(11C; t1/2 = 20.4 min) or fluorine-18 (18F; t1/2 = 109.7 min).  Unfortunately, the sensitivity of SQ-MS 
is not sufficient to detect the radiolabelled species themselves in typical clinical-grade 
radiopharmaceutical formulations. For example, clinical-grade 18F-labelled PET radiotracers have 
typical specific activities around 5 Ci/µmol with administered radioactive doses in humans around 10 
to 20 mCi.14 For an average human male (~75 kg) this administered dose of radiotracer equates to 
around ~2 to 4 nmol (ca. 25 to 50 pmol/kg body weight). Given the theoretical maximum specific 
activity of fluorine-18 (1712.9 Ci//µmol), typical 18F-radiotracers have an isotopic dilution factor of 
around ~350 (equivalent to approximately one radioactive atom for every 350 non-radioactive 19F 
atoms; ~0.3%). Hence, the number of moles of radioactive species present in a standard human 
injection is around 6 to 12 pmol. For carbon-11 radiotracers, even smaller quantities of radiolabelled 
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material are produced in clinical productions. For example, the number of atoms contained in the 10 
mCi of 11C is ~6.5 x 1011 atoms, equivalent to 1.08 x 10-12 moles.15 Using a typical radioactive 
concentration of 10 mCi/mL, a 5 µL injection used for standard LC/MS analysis represents only ~5 
femtomoles of the 11C-labeled radiotracer. These calculations illustrate that the vast majority of PET 
radiotracers observe the tracer principle,16 wherein the chemical dose of administered PET 
radiotracers is so small that the agents have no effect on biochemical processes in vivo. Although a 
SQ-MS cannot determine the amount of radioisotope in a sample, MS has found applications in PET 
radiochemistry,17-19 specifically for radiometabolite analysis.20 
 Herein, we showcase applications of a compact SQ-MS in our laboratories.  Specifically, we 
describe the use of SQ-MS for: 1) coupling with a novel pre-concentration system to detect dilute 
radiopharmaceutical formulations and application of this system in metabolite analyses; 2) 
optimization of radiochemical reactions and simultaneous characterization of 11C- and 18F-labeled 
radiotracers; 3) purification and identification of radiometal complexes with 89Zr and Pd metal-
catalyzed radiofluorination reactions.  
3. Integration of a Pre-concentration System to a SQ-MS 
For practical applications of SQ-MS in PET radiochemistry, it is necessary to increase the sample 
concentration. The major benefit of a pre-concentration step in PET radiotracer analysis is the ability 
to concentrate the non-radioactive (cold) mass associated with the radioactive species. Concentrating 
the sample also helps to eliminate (or significantly reduce) interferences, such as salts (trifluoroacetic 
acid, phosphate etc.) or high concentrations of solvents such dimethyl sulfoxide (DMSO), acetonitrile 
or other organic solvents that may affect the chromatography directly or cause suppression of the 
mass spectrometry signal. Pre-concentration systems have been used in the determination of metals 
and ions since the late 1970’s.21 Initially these systems found their major use in groundwater analysis 
and generally consist of an injector system where the injection loop has been replaced by an 
adsorbent.2, 22-24 However, other modifications including the replacement of the injection loop with 
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an electrochemical cell for the pre-concentration of divalent metals25 were reported. The basic 
trapping system replaces the injection loop with a trapping cartridge and the rest of the system remains 
as standard for the chromatography system. The sample may require dilution using water to allow the 
desired materials to be trapped and can be washed with water or a suitable eluting solvent to remove 
salts, ion pairs etc. that may interfere with the chromatography or to eliminate / reduce materials that 
are not well retained but are present in high concentration. From a radiochemical perspective, these 
pre-concentration systems are analogous to solid-phase strong cation exchange methods that are used 
to trap 68Ga3+ ions and purify the radionuclide from non-radioactive impurities (Zn2+, Fe3+ etc.) and 
radioactive materials (68Ge) that are leached during standard 68Ga-generator elution protocols.  
 
Figure 1. A: In this position the trapping cartridge is cleaned for trapping by washing with ethanol 
and then water. The sample is then applied to the trapping cartridge to perform the concentration of 
the materials. If necessary, the sample may require dilution or adjustment of the pH to affect the 
retention of the material on the trapping cartridge. The trapping cartridge is then washed with water 
or other solution to remove interfering materials. At the same time, the analytical system is 
equilibrated to minimize the analysis time. B:  In this position, the trapping cartridge is moved into 
the flow path with the analytical column to perform the analytical analysis. C: The trapping cartridge 
(Valco Instruments Co. Inc, Houston, TX, Finger-tight cartridge assembly #SFECH412) can be 
packed by the user with any standard solid phase extraction or resin packing.  
An example of the utility of the pre-concentration system is shown in Figure 2, where for 













peptide (Ac-Pro-Phe-Arg-Ser-Val-Gln-NH2) was injected onto the LC/MS system.  The protonated 
molecular ion peak, [M+H]+, can be observed in the mass spectrum at an m/z 774.6 (monoisotopic 
MW =  773.4); however, there is considerable noise in the spectrum. The additional noise in the mass 
spectra makes it difficult to determine which of the peaks are attributed to the desired compound.  It 
is possible to concentrate the sample by evaporation, assuming the sample is stable to the process.    
 
Figure 2. Mass spectrum obtained from a 5 µL injection of the Kallikrein inhibitor peptide (Ac-Pro-
Phe-Arg-Ser-Val-Gln-NH2) solution (0.16 nmol /mL) on to the LC/MS system. The intensity of the 
[M+H]+ peak is similar to the other noise peaks. 
 
The use of the pre-concentration system allows the user to increase the amount of mass 
injected on to the LC-SQ-MS system with minimal manipulations and with minimal losses. Figure 3 
shows the effect of concentrating a 1 mL sample of the 0.16 nmol/mL solution of the same Kallikrein 
Inhibitor peptide (Ac-Pro-Phe-Arg-Ser-Val-Gln-NH2) observed in Figure 2. In this case, 
concentrating the sample increased the amount of peptide to be injected on to the LC/MS system to 
~160 pmol.  The ability to wash the trapping cartridge, after the trapping of the compound of interest, 
reduces the salts and solvent present while not increasing the volume of the sample injected to the 
analytical column. The mass spectrum observed in Figure 3 is absent of other interfering peaks and 
the signal to noise is extremely high. Thus, pre-concentration greatly improved the signal-to-noise 












Figure 3. Mass spectrum obtained from 1 mL of the Kallikrein Inhibitor peptide (Ac-Pro-Phe-Arg-
Ser-Val-Gln-NH2)solution (0.16 nmol /mL), concentrated on the trapping cartridge containing a 
hydrophilic modified styrene polymer solid phase extraction material (HLB). The cartridge was then 
washed with water (5 mL, LC/MS grade) to remove contaminants such as saline and was then injected 
on to the LC/MS system. The protonated molecular ion, [M+H]+, is the only peak seen in the mass 
spectrum.  
 
4.0 Metabolite Analysis 
Given the importance of assessing the metabolism of a radiopharmaceutical in vivo for quantitative 
analysis it is not surprising that LC/MS has found applications in PET imaging studies.20  A basic 
outline of the methodology for LC/MS based metabolomics was described by Zhou et al.26 With 
access to a high sensitivity triple quadrupole MS, Shetty et al27 determined that it is possible to 
observe 11C-labeled species and their respective 12C ([M+1]) isotopologues/carriers for four PET 
radiotracers. While the sensitivity of the SQ cannot observe the radioisotopically labelled species, it 
is still possible to obtain data by observing the small amount of “carrier” material or metabolites when 
present. Typically, when performing metabolite analysis on a new radiotracer, the most common 
types information obtained is simply to what extent metabolites are observed and whether these 
metabolites are more or less lipophilic that the parent radiotracer. Detailed knowledge of the chemical 
composition and structure of radiometabolites is often lacking. A common method for the analysis of 
metabolites is a column-switching approach reported by Hilton et al.28  Column-switching HPLC has 
been used extensively in the analysis of drugs and their metabolites in plasma.29, 30 The materials 
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without loss of materials during the transfer. In the paper by Hilton sample sizes of up to 4 mL of 
plasma were used. Recently, we reported an automated version of this column-switching HPLC 
system.31, 32 
 An alternative pre-concentration methodology for dilute radiotracer samples, including 
plasma, takes advantage of thin layer chromatography (TLC) to separate the intact radiotracer33, 34 
from metabolites. The benefit of using TLC is two-fold: first, larger amounts of material can be 
spotted on to the TLC plate (up to 250 µL of plasma) without the need to remove all proteins from 
the sample; second, by extending the time that the TLC plate is exposed to the phosphor imager plate 
of a Cyclone Plus Storage Phosphor System (PerkinElmer, Inc., Waltham, MA  USA) or using an 
AR-2000 (Eckert & Ziegler Radiopharma Inc., Hopkinton MA, USA) the entire TLC lane can be 
imaged over a set period of time or can be set to continue to collect data until a sufficient number of 
counts are detected.  
 
Figure 4. Radiochemical synthesis of the glycogen synthase kinase 3 (GSK-3) radiotracer, [11C]PF-
367 
Figure 4 shows the radiochemical methylation reaction of the phenolic precursor to form the 
GSK-3 radiotracer [11C]PF-367. TLC metabolite analysis was performed on a 1 mL plasma sample 
obtained at various times post-injection of the glycogen synthase kinase 3 (GSK-3) radiotracer, 
[11C]PF-367 (Figure 4, monoisotopic molecular weight 361.1) to which 135µg/ kg of “cold” PF-367 
had been administered.35 Analysis of the TLC plate by MS-SQ was performed by automatically 








Figure 5. TLC/MS of the plasma sample, [11C]PF-367. The arrows indicate the positions that 
were sampled by the TLC/MS system. The silica is sometimes removed during the process and this 
is indicated by the dark oval. For the 1 minute post injection plasma sample, the blue arrows indicate 
the position where the proteins, di and tri-glycerides were observed. The green arrow indicates the 
position where the parent compound, [11C]PF-367 was observed. 
This analysis resulted in between 30-35 mass spectra of each plasma sample analyzed (Figure 
5). Each sample was initially analyzed by SQ-MS to determine if they contained the core radiotracer 
structure. In the case of PF-367, the most intense peaks, observed were for the [M+Na]+, and were 
seen at m/z 384.1 for the parent compound + sodium ion and m/z 370.1 for the precursor + sodium 
ion (Figure 6). 
 
Figure 6. Mass spectra of compounds identified in the TLC analysis of the plasma sample obtained 
at 1 minute post injection A: Spectrum obtained from material at an Rf of 0 - 0.1 (Blue arrows in 
Figure 5) and indicates the presence of proteins, triglycerides and diglycerides. C: Spectrum from 
peak at Rf = 0.9 (Green arrow in Figure 5) indicates the presence of the intact PF-367. 
To highlight the use of the trapping system method (vide supra) for the determination of metabolites, 
the plasma sample obtained at 10 minutes post-injection of the glycogen synthase kinase 3 (GSK-3) 
radiotracer, [11C]PF-367 (Figure 4) to which 135µg/ kg of “cold” PF-367 had been administered.35 In 
this case, ~100 µL of plasma was injected onto the trapping cartridge followed by washing with 5 mL 
of 1% acetonitrile / water to remove salts. The material trapped was analyzed by LC/MS and the 


















to obtain the intensity of the protonated parent compound ([M+H]+ = 362.1) and the protonated 
precursor ([M+H]+ = 348.1). The XIC is a means of obtaining a chromatogram without the other 
masses which are not related to the ions being investigated. The metabolism of a compound may be 
predicted by using the MetaPrint2D-React metabolic product predictor, which can be found on the 
Center for Molecular Informatics website (University of Cambridge, http://www-
metaprint2d.ch.cam.ac.uk/metaprint2d-react/). In the case of PF-367, the major predicted metabolite 
coincides with the observed demethylated phenol, production of which is attributed to metabolism by 
P-450 enzymes in vivo.36 
 
Figure 7. Plasma metabolite sample 10 minutes post-injection of the glycogen synthase kinase 3 
(GSK-3) radiotracer, [11C]PF-367 (Figure 4) to which 135µg/ kg of “cold” PF-367 had been 
administered. A: Total ion chromatogram of PF-367 plasma sample. B: Extracted ion chromatogram 
(XIC) of the protonated primary expected metabolite m/z 348.1 (demethylated phenol). C: Extracted 
ion chromatogram (XIC) of the protonated parent compound of [M+H]+ m/z 362.1.  
5. Analysis of PET reactions to optimize reaction conditions 
Advantages of using MS during the optimization process for producing radiotracers are illustrated by 
our [11C]CO2 fixation reactions,37-41 which can now be performed “in-loop”  to form 11C-labelled 
carbamates, oxazolidinones and ureas (Figure 8).42 Sufficient non-radiolabeled mass of material is 





































the radiosynthesis. It is noteworthy that for these reactions, the intermediates and products formed 
during the reactions are readily ionized using and electrospray ionization (ESI) source yielding high 
signal-to-noise ratios.  
 
 
Figure 8. A: Radiosynthesis of the desired product, methyl N-benzylcarbamate using [11C]CO2 
fixation methodology to form the intermediate [11C]isocyanate, which then reacts with methanol to 
produce the carbamate. B: By-product of the radiosynthesis where the symmetrical urea, 1,3-
dibenzylurea, is formed by reaction of the intermediate [11C]isocyanate reacts with another molecule 
of benzylamine. 
 Interestingly, the major 11C-labelled product that was obtained had a different retention time 
than the standard molecule, methyl N-benzylcarbamate. The results of the radioactive-LC/MS 
analysis are shown in Figure 9. It should be noted that the radioactive species, observed at retention 
times of ~7.8 and 8.1 minutes were not observed using SQ-MS, but the small amount of non-
radioactive mass (always present during the radiosynthesis) was seen. The mass spectrum of the major 
peak at a retention time of ~7.8 min had a major ion at m/z 241.1, which did is not the desired 
carbamate, but corresponds to the protonated molecular ion, [M+H]+ of the symmetrical urea, N,N′-
diphenylurea (Figure 9, inset A). The minor radioactive peak, at the retention time of ~8.1 min, had 
a major ion that did correspond to the protonated molecular ion [M+H]+ ion of the desired carbamate, 
methyl N-benzylcarbamate (Figure 9, inset B) 
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Figure 9. Radio-HPLC showing the radiation detector output for products of the [11C]CO2 fixation 
with benzylamine and methanol. Inset A: Mass spectrum obtained from the major radiation peak, 
(Red arrow) which does not correspond to the desired methyl N-benzylcarbamate, but to the [M+H]+ 
of N,N’-diphenylurea, m/z 241.1. Inset B: Mass spectrum obtained from the minor radioactive peak 
at a retention time of ~8.1' (Blue arrow), which has the correct [M+H]+ ion for the desired carbamate, 
m/z 166.1  
 By knowing the identity of the major impurity (N,N′-diphenylurea) observed in the radio-
HPLC of the initial reaction attempted, it was possible to modify the reaction conditions to minimize 
the formation of the symmetrical urea (Figure 10). Judicious control of the reaction conditions 
allowed chemoselective synthesis of the desired 11C-carbamate as the major product.42  
 
Figure 10. With insight from MS, the reaction conditions were altered to synthesize the desired 
carbamate as the major product, and the symmetrical urea was significantly suppressed.  
In the past, to obtain positive and negative ion scans it was necessary to perform two different 
analyses. With improvements in electronics and mass spectrometer design, most commercial SQ-MS 
systems now can rapidly change the parameters of the ion source and mass spectrometer. The typical 
use of this switching ability is to obtain both positive and negative ions at the same time. However, 
it is also possible to use the same polarity but to alter the ion source characteristics, such as source 
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effectively occurs simultaneously, and both molecular ion and fragmentation data can be obtained in 
the same analysis.  An example of this is illustrated in Figure 11, where the standard ion source 
settings and ion source settings with the source voltage raised 30V above the standard settings. With 
the standard ion source settings, only the protonated molecular ion is observed for the Kallikrein 
Inhibitor peptide (Ac-Pro-Phe-Arg-Ser-Val-Gln-NH2). The mass spectrum obtained using the ion 
source setting with the higher source voltage, it can easily be seen that there has been increased 
fragmentation and this information can be used to determine additional structural information.  
 
Figure 11. A: Mass spectrum which shows only the protonated molecular ion obtained during LC-
SQ-MS run using the standard ion source parameter which minimize fragmentation, Inset: Expanded 
plot showing molecular ion region; B: During the same run as above, the ion source voltage was 
increase by 30V to induce fragmentation and as observed in the mass spectrum, there is further 
information which can aid in the elucidation of structure. 
 
 
6. Purification and identification of metal complexes  
The development of radiotracers based on radioactive metal ion complexes is becoming increasingly 
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chemistry is employed to attach radiometal ions to biological targeting vectors such as peptides, 
proteins, antibodies, and more elaborate systems based on nanoparticles.43, 44 Coordination of the 
metal ion relies on derivatizing the vector with a bifunctional chelate (BFC). The BFC is chosen to 
present an optimum set of donor atoms to facilitate stable and selective metal ion complexation, as 
well as offer a reactive handle to allow covalent functionalization of the vector molecule.  Ideally, the 
metal ion complex should be thermodynamically, kinetically and metabolically stable to prevent 
unwanted escape of the metal ion in vivo. In addition, the conjugation chemistry is often chosen to 
minimize the rate of degradation or loss of the metal ion complex from the vector. Nevertheless, for 
most metal ion BFC systems, a certain degree of degradation or loss of the radiometal ion is 
commonly observed. For example, Cu2+ ions can be coordinated by various chelates including the 
macrocycles DOTA, NOTA, NODGA and CB-TE2A.45  Dramatic differences in the biodistribution 
profiles have been observed for systems that employ these different chelates with high liver uptake 
often attributed to demetallation of the Cu2+ ion in vivo. Understanding the nature of the metal ion 
complexes, and potential degradation products is crucial for future design of new metal ion chelates.  
 Increasing interest in the use of 89Zr-radiolabeled antibodies for immuno-PET imaging 
provides a suitable case-study. Zirconium-89 is a positron-emitting radionuclide with a has a half-life 
of 78.4 hours and exists as the 4+ metal ion, and is readily coordinated by the hexadentate, tris-
hydroxamate ligand, desferrioxamine B. Density functional theory (DFO) calculations have predicted 
that, due to the increased size of the first coordination sphere, Zr4+ ions coordinated by DFO have the 
potential to increase their coordination number from between 6 and 8 donor atoms.46 No crystal 
structures of the predicted [Zr(DFO)(H2O)2]+ are available but MS data confirm the DFT predictions 
which suggest that the water molecules are loosely bound and kinetically labile (Figure 12). 
 While most human applications of 89Zr-radiolabeled antibodies have found that the 89Zr-DFO 
complex remains stable in vivo, concern still exists about the potential loss of 89Zr ions from the 
chelate and associated problems for radiation dosimetry. In mouse models 89Zr-labeled antibodies 
typically show accumulation of the radioactivity in bone that reaches ca. 5 – 10% ID/g of administered 
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dose.46, 47 Interestingly, bone accumulation of 89Zr is typically found to be higher in animal models 
that have tumour models which are positive for the target antigen which points toward specific 
intratumoural metabolism as the source of the bone seeking 89Zr-species. Metabolic degradation of 
the bifunctional linker and potential demetallation are two possible explanations for the bone tropism. 
However, at present no studies have confirmed the chemical nature of the 89Zr-species that is released 
from the 89Zr-DFO-antibody constructs. Studies have shown that 89Zr ions administered as either the 
tetraoxalate complex, [89Zr(C2O4)4]4- or as the ZrCl4 species dissolved in a phosphate buffer show 
high accumulation of radioactivity in the bone.48 It is likely that detailed MS studies will be required 
to solve these outstanding questions about zirconium metabolism.  
 
Figure 12. A: Structure of the zirconium desferrioxamine complex. Note: loosely associated solvent 
water molecules are not observed in the MS. The monoisotopic molecular weight of [Zr(DFO)]+, 
C25H45N6O8Zr, is 647.2; B: the predicted spectrum of [Zr(DFO)]+; C: total ion chromatogram from 
the flow injection analysis (FIA) of the [Zr(DFO)]+complex. D: the spectrum obtained by FIA 





















A further example is the development of a new purification method for a palladium(IV) fluoride 
complex. Hooker & Ritter et al. disclosed the radiosynthesis and utility of a novel Pd(IV)18F complex 
that was able to undergo fluorination reactions with palladium aryl complexes to yield 18F-aryl 
fluorides.49 This discovery was important to the field of PET radiochemistry with [18F]fluoride, as 
now the ability to carry out “pseudo-electrophilic” fluorination reactions without the need for [18F]F2 
gas and its derivatives (e.g. [18F]Selectfluor™) meant that readily available and high specific activity 
[18F]fluoride could be used for 18F-labelling of non-activated aromatic rings.  The purification of 
[18F]Pd(IV)F requires the use of a polypyridine resin (JandaJel™-polypyridine)( Figure 13). 
However, this resin is no longer commercially available and a new method was needed to purify the 
complex.  
 
Figure 13. Radiosynthesis of [18F]Pd(IV)F using JandaJel™-polypyridine for  purification of the 
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Since the fluorinated species was the desired product to be isolated from the reaction mixture, we 
postulated that the Pd(IV)F complex could be purified using HPLC, however the stability of this 
complex towards HPLC conditions was unknown. We used LC/MS to test the viability of HPLC 
purification (Figure 14). The complex was initially injected onto the LC/MS using acetonitrile and 
formic acid as the eluent. Data from the MS showed that under these conditions the Pd(IV)F complex 
was not stable as the loss of a pyrazole from the tetrpyrazolborate ligand was observed Figure 14.  
This result suggested that acids should be avoided in the purification step and that the ideal HPLC 
solvent system should be carried out at neutral or near neutral pH. When the HPLC purification was 
repeated using acetonitrile and potassium triflate (0.1M) the MS showed that the major product was 
indeed the Pd(IV)F complex.   
 
 
Figure 14. Upper two traces: initial purification methodology tested and resulted in the loss of one 
of the pyrazole groups. Lower 2 traces: Final purification methodology which resulted in the major 
































































Isolation of the complex from the HPLC and subsequent analysis by MS demonstrated that HPLC 
purification was a viable method to purify Pd(IV)F.  Further investigation of the observed isotope 
pattern of the MS showed that it matched well with the predicted isotope pattern of the complex 
(Figure 15).  
 




Herein we have described a pre-concentration system integrated to an SQ-MS to detect dilute 
radiopharmaceutical formulations and metabolites.  We also show examples of how SQ-MS was used 
for optimization of radiochemical reactions, identification of radiometal complexes and development 
of a new purification methodology for radiofluorination reactions. The examples of SQ-MS in our 
PET radiochemistry laboratories presented herein hopes to inspire the radiochemistry community as 
well as researchers involved in organic synthesis, organometallic chemistry, preclinical and clinical 
translation to make more use of this readily available instrumentation in both basic and applied 
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